Comprehensive care of the epilepsy patient--control, comorbidity, and cost.
Traditionally, control of seizures in patients with epilepsy is viewed as the most important clinical outcome. Yet, current antiepileptic drugs (AEDs) do not always achieve this. Around 30-40% of patients remain uncontrolled despite pharmacological intervention. Poor tolerability of AEDs is a large part of the problem and contributes as much to the overall effectiveness of therapy as efficacy. Comorbid conditions are present in many patients, and appropriate management of these can further improve seizure control and quality of life. Patients with epilepsy often experience--among other disorders--neuropsychological effects, migraines, and psychological problems (especially anxiety and depression). Sleep disturbances are also common and have been shown to contribute to the intractability of seizures in some patients. Many anticonvulsant treatments have the potential to improve--or in some cases worsen--these concurrent conditions, and these properties should therefore be considered in the total care of the patient. Finally, the costs of uncontrolled epilepsy are measured not only in terms of direct healthcare-related costs, but also in terms of lost productivity and opportunity. The indirect costs of epilepsy are substantial and account for 70-85% of total disease-related costs. Patients with uncontrolled seizures contribute disproportionately to healthcare costs, reinforcing the need for the development of newer AEDs with improved profiles of efficacy and tolerability, but with minimal adverse effects on behavior, cognition, and sleep.
Bazil
Carl W
CW
Comprehensive Epilepsy Center, Columbia University, New York, New York 10032, USA. cwb11@columbia.edu
D000927:Anticonvulsants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015897:Comorbidity; D003191:Comprehensive Health Care / Q000191:economics / Q000379:methods*; D017281:Cost of Illness; D004827:Epilepsy / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D017048:Health Care Costs; D006296:Health Services / Q000706:statistics & numerical data; D006304:Health Status; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D015995:Prevalence; D011788:Quality of Life; D055502:Secondary Prevention; D012890:Sleep / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000139:chemically induced
D000927:Anticonvulsants